As a client and partner of the European Bank for Reconstruction and Development (EBRD) in the fight against antimicrobial resistance (AMR), BioChimPharm was included in the 2023 EBRD Sustainability Report. | With the support of the EBRD, as well as other local and international partners, ” BioChimPharm ” modernized the historical phage factory. With the compliance to standards recognized in the European Union, BioChimPharm received GMP certification.

As a result of the implementation of the 6.5 million euro project of renovation and modernization of the enterprise, the company took a leading position in the fight against the global antibiotic resistance crisis.

“Bacteriophages, also known as phages, are microorganisms, that specifically target bacteria. Phage therapy involves using phages to treat bacterial infections. In contrast to many antibiotics, phages target bacterial strains or species more narrowly, making phage therapy an attractive alternative for managing infections. Modernising BioChimPharm’s manufacturing plant in compliance with GMP will enable it to scale up production and potentially export phage products” – states the report.